{
    "clinical_study": {
        "@rank": "16494", 
        "arm_group": [
            {
                "arm_group_label": "Levetiracetam IV infusions in Japanese", 
                "arm_group_type": "Experimental", 
                "description": "Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Japanese subjects"
            }, 
            {
                "arm_group_label": "Levetiracetam IV infusions in Caucasian", 
                "arm_group_type": "Experimental", 
                "description": "Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Caucasian subjects"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the pharmacokinetics of levetiracetam following single and multiple 15-minute\n      intravenous infusions of 1500 mg levetiracetam between Japanese and Caucasian healthy male\n      subjects"
        }, 
        "brief_title": "Multiple-dose Study of Levetiracetam Injection in Japanese and Caucasian Healthy Males", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy Japanese and Caucasian males with the age between 20 and 40 years old,\n\n          -  with the body mass index between 20 and 25,\n\n          -  with the body weight between 60 and 80kg\n\n        Exclusion Criteria:\n\n          -  subjects who have a history or presence of drug addiction or excessive use of alcohol\n\n          -  current smokers and former smokers who have given up since less than 6 months before\n             the first dose\n\n          -  heavy caffeine drinker"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01725009", 
            "org_study_id": "EP0038"
        }, 
        "intervention": {
            "arm_group_label": [
                "Levetiracetam IV infusions in Japanese", 
                "Levetiracetam IV infusions in Caucasian"
            ], 
            "description": "Strength, 100 mg/mL; Form, concentrate for solution for infusion; Frequency, twice a day; Duration, 7 days", 
            "intervention_name": "Multiple 15-minute intravenous infusions of 1500 mg levetiracetam", 
            "intervention_type": "Drug", 
            "other_name": "E-Keppra"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Etiracetam", 
                "Piracetam"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Healthy volunteers", 
            "Japanese", 
            "Caucasian"
        ], 
        "lastchanged_date": "March 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan"
                }, 
                "name": "01"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-center, Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Levetiracetam Administered as Intravenous Infusion in Japanese and Caucasian Healthy Male Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum plasma concentration after a single dose (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of Intravenous (IV) infusion"
            }, 
            {
                "measure": "Area under the curve from zero to the time of the last quantifiable concentration after a single (AUC(0-t))", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion"
            }, 
            {
                "measure": "Area under the plasma concentration time curve from zero to infinity after a single dose (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion"
            }, 
            {
                "measure": "Body-weight normalized maximum plasma concentration after a single dose (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion"
            }, 
            {
                "measure": "Body-weight normalized area under the curve from zero to the time of the last quantifiable concentration after a single, (AUC(0-t))", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion"
            }, 
            {
                "measure": "Body weight normalized area under the plasma concentration time curve from zero to infinity after a single dose, (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion"
            }, 
            {
                "measure": "Maximum plasma concentration at steady state after multiple doses (Cmax,ss)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion."
            }, 
            {
                "measure": "Area under the curve over a dosing interval at steady state  after multiple doses (AUC\u03c4ss)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion."
            }, 
            {
                "measure": "Body-weight normalized maximum plasma concentration at steady state  after multiple doses (Cmax,ss)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion."
            }, 
            {
                "measure": "Body-weight normalized area under the curve over a dosing interval at steady state  after multiple doses (AUC\u03c4ss)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01725009"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the curve over a dosing interval, (AUC\u03c4 (\u03c4 = 12 hours))", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion"
            }, 
            {
                "measure": "Time to maximum plasma concentration after a single dose (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion."
            }, 
            {
                "measure": "Terminal elimination half-life after a single dose (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion."
            }, 
            {
                "measure": "First order terminal elimination rate constant after a single dose (\u03bbz)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion."
            }, 
            {
                "measure": "Total body clearance after a single dose (CL)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion."
            }, 
            {
                "measure": "Volume of distribution during terminal phase after a single dose (Vz)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion."
            }, 
            {
                "measure": "Mean residence time after a single dose (MRT)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion."
            }, 
            {
                "measure": "Time to maximum plasma concentration at steady state after multiple doses (tmax,ss)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion."
            }, 
            {
                "measure": "Total body clearance at steady state after multiple doses (CLss)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion."
            }, 
            {
                "description": "LF = AUC\u03c4ss / AUC", 
                "measure": "Linearity factor after multiple doses (LF)", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of the first IV infusion and at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of the last IV infusion."
            }, 
            {
                "description": "RAUC = AUC\u03c4ss / AUC\u03c4", 
                "measure": "Accumulation ratio (RAUC) after multiple doses", 
                "safety_issue": "No", 
                "time_frame": "Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of the first and the last IV infusions"
            }
        ], 
        "source": "UCB, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UCB Japan Co. Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}